Immutep Ltd · ASX:IMM
Immutep — Conference Presentation (September 2022)
27 slides from Immutep's conference presentation, September 2022
Slide 1: A Global Leader in LAG-3 Therapeutics in Oncology and Autoimmune Disease
A Global Leader in LAG-3 Therapeutics in Oncology and Autoimmune Disease Corporate Presentation – September 2022 (ASX: IMM, NASDAQ: IMMP)
Slide 2: Forward-Looking Statements
Forward-Looking Statements The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarificati
Slide 3: Immutep Overview
Immutep Overview Pioneering LAG-3 Portfolio Collaborations with Industry Leaders in Oncology & Autoimmune Disease Immutep is a pure-play LAG-3 clinical-stage company with four product candidates that address significant market opportunities in oncology & autoimmune disease Compelling Clinical Data G
Slide 4: Immutep LAG-3 Pipeline
Immutep LAG-3 Pipeline Program Preclinical Phase I Phase II Late Stage Commercial Rights Metastatic Breast Cancer (Chemo-IO) - AIPAC 1st Line Head and Neck Squamous Cell Carcinoma (IO-IO) - TACTI-003 Eftilagimod Alpha (efti or IMP321) 2nd Line Head and Neck Squamous Cell Carcinoma (IO-IO) - TACTI-00
Slide 5: LAG-3: Approved Checkpoint with Unique Characteristics
LAG-3: Approved Checkpoint with Unique Characteristics Immune system’s role in controlling cancer has led to regulatory approval of immunotherapies targeting CTLA-4, PD-1, and now LAG-3 checkpoints Cytotoxic T lymphocyte Programmed Cell Death Lymphocyte Activating Antigen-4 (CTLA-4) Protein-1 (PD-1)
Slide 6: LAG-3 Therapeutics for Oncology
LAG-3 Therapeutics for Oncology
Slide 7: Multiple Companies Targeting LAG-3 Inhibition
Multiple Companies Targeting LAG-3 Inhibition Releasing the Brake on T cells Relatlimab Approval in Mar 2022 Blocking LAG-3 / MHC II interaction increases cytotoxicity of pre-existing CD8 T cell response Anti-LAG-3 mAb LAG-3 MHC II Resting Activated dendritic cell T cell Immutep developed the first
Slide 8: First-in-Class Positioning in LAG-3 Oncology Landscape via Efti
First-in-Class Positioning in LAG-3 Oncology Landscape via Efti Pushing the Accelerator on the Immune System APC activation with Efti Anti-tumor immune cell activation Eftilagimod alpha Efti (Efti) APC LAG-3 MHC II Dendritic Cells T-cells NK Cells Monocytes Human IgG1 Broad activation of immune syst
Slide 9: Efti's Synergistic Effects with Chemotherapy & Immunotherapy
Efti’s Synergistic Effects with Chemotherapy & Immunotherapy Chemotherapy releases Activated APCs via efti Cytotoxic CD8+ T cells & other Efti enhances anti-PD-1 therapies’ cancer antigens through acquire cancer antigens & cells key to immunotherapy ability to enable adaptive immune cancer cell deat
Slide 10: Pipeline in a Product with Broad Potential
Pipeline in a Product with Broad Potential Anti-PD1/PDL1 mAb clinical trials landscape* Efti Clinical Trials Confirm Broad Combination Potential IO-IO Chemo-IO Combination Combination Triple Chemo-IO-IO Combination Efti + Anti-PD-1 (pembrolizumab) Head & Neck Squamous Cell Carcinoma (1L & 2L), Non-S
Slide 11: Phase II Trial Evaluating Efti + Pembro in 1L NSCLC
Phase II Trial Evaluating Efti + Pembro in 1L NSCLC TACTI-002/KEYNOTE-798: 1st Line Non-Small Cell Lung Cancer (Part A) TACTI-002: Two ACTive Immunotherapeutics in NSCLC & HNSCC Baseline characteristics for PD-L1 All Comer Trial Part A (N=114) Age, median (range), years 67 (44-85) Sex, n (%) Female
Slide 12: Encouraging Clinical Results; Primary Objective Achieved
Encouraging Clinical Results; Primary Objective Achieved TACTI-002/KEYNOTE-798: 1L NSCLC (Part A) Efti + Keytruda Keytruda Keytruda Combination* Monotherapy Monotherapy Clinical Trial & Phase P2 (TACTI-002/KEYNOTE-798) P3 (KEYNOTE-042) P3 (KEYNOTE-024) • Primary objective achieved (ORR >35%) Patient
Slide 13: Robust ORR/PFS Across Entire PD-L1 Spectrum vs Pembrolizumab
Robust ORR/PFS Across Entire PD-L1 Spectrum vs Pembrolizumab TACTI-002/KEYNOTE-798: 1L NSCLC (Part A) Overall Response Rate (ORR) Median Progression Free Survival (PFS) (with 95% confidence intervals) (by PD-L1 TPS Score) Efti + pembro Pembro Efti + pembro Pembro 9.3 months 1-49% TPS 1-49% 4.2 month
Slide 14: Deep and Durable Responses
Deep and Durable Responses TACTI-002/KEYNOTE-798: 1L NSCLC (Part A) Tumor Burden Reduced in Majority of Patients 100 75 baseline baseline 50 from 25 changefrom 0 • Responses are deep & long-lasting; median DoR not yet reached Best%%change -25 -50 • 80% (35) of responses1 already confirmed & 11.4% (5
Slide 15: Benchmarking against IO & IO-Chemo Combinations
Benchmarking against IO & IO-Chemo Combinations TACTI-002/KEYNOTE-798: 1L NSCLC (Part A) Toxicity: TPS Treatment Efficacy(1) AEs leading to disc. Efti + Pembro ORR 45.5% PFS 8.4 mos < 10% ≥ 1% Pembro mono ORR 27.5% PFS 5.4 mos 1-14% Ipi + Nivo(2) ORR 36% PFS 5.1 mos 18% Efti + Pembro ORR 41.7% PFS 9
Slide 16: Triple IO-IO-Chemo Combination Trial
Triple IO-IO-Chemo Combination Trial INSIGHT-003: Phase I in Solid Tumors Focusing on NSCLC Adenocarcinomas INSIGHT-003 - Third arm (Stratum C) of ongoing Investigator-initiated study focusing on NSCLC adenocarcinomas Triple Combination Approach to Capitalize on Efti’s Synergistic Effects with Chemo
Slide 17: Strong, Long-Lasting Efficacy in 2L HNSCC
Strong, Long-Lasting Efficacy in 2L HNSCC TACTI-002/KEYNOTE-798: 2nd Line Head & Neck Squamous Cell Carcinoma (Part C) Responses at all PD-L1 levels including 5 iCRs Efti + Keytruda Keytruda Combination* Monotherapy# Best % change from baseline Clinical Trial & Phase P2 (TACTI-002/KN-798) P3 (KN-040
Slide 18: Robust ORR, CR and DoR for Efti + Pembro vs Pembro
Robust ORR, CR and DoR for Efti + Pembro vs Pembro TACTI-002/KEYNOTE-798: 2L HNSCC (Part C) Overall Response Rate Complete Response Rate Duration of Response (DoR)# Pembro mono 1 Efti + Pembro 64.3% 13.5% More than double response Eight-fold increase in CR rates across all PD-L1 levels rate with eft
Slide 19: Fast Track Designation in 1L HNSCC
Fast Track Designation in 1L HNSCC TACTI-003: Phase IIb in 1st Line Head and Neck Squamous Cell Carcinoma (HNSCC) Status: • Recruiting (~30% enrolled; recruitment accelerating as further sites have been activated*) • FDA Fast Track designation on strength of TACTI-002 data in 2L HNSCC Design: • Rand
Slide 20: Efti + Anti-PD-L1 (Avelumab) in Advanced Solid Tumors
Efti + Anti-PD-L1 (Avelumab) in Advanced Solid Tumors INSIGHT-004: Phase I in Various Advanced Solid Tumors Histologically confirmed locally or Stratum D Dose escalation study evaluating efti in combination advanced metastatic Patient eligible to treatment Concurrent avelumab (no more than 3 prior l
Slide 21: AIPAC Phase IIb: Significant OS Improvement Across Multiple Pre-Specified Subgroups with Superior QoL
AIPAC Phase IIb: Significant OS Improvement Across Multiple Pre-Specified Subgroups with Superior QoL AIPAC: Active Immunotherapy PAClitaxel in HER2–/ HR+ metastatic breast cancer Phase IIb Trial AIPAC: Multicenter, placebo-controlled, double-blind, Low Monocytes Luminal B 1:1 randomized Phase IIb s
Slide 22: Substantial Increase in Monocytes, CXCL10 & Cytotoxic CD8+ T Cells Correlated to Stronger OS
Substantial Increase in Monocytes, CXCL10 & Cytotoxic CD8+ T Cells Correlated to Stronger OS AIPAC: Active Immunotherapy PAClitaxel in HER2–/ HR+ metastatic breast cancer Phase IIb Trial Statistically-Significant Increase Statistically-Significant Correlation: Fold Change of CD8+ & CD4+ T Cells, of
Slide 23: LAG-3 Therapeutics for Autoimmune Disease
LAG-3 Therapeutics for Autoimmune Disease
Slide 24: LAG-3: A Key Target in Autoimmune Diseases
LAG-3: A Key Target in Autoimmune Diseases Present Approaches Fight the Symptoms of Autoimmune Diseases Treating general inflammation: Corticoids, methotrexate, anti-TNF-α, -IL-6, -IL-17, -IL-23 mAbs Future Approaches Target the Causes of Autoimmune Disease Treating the disease process: Targeting au
Slide 25: IMP761: Broad Potential Targeting Auto-Reactive Memory T Cells
IMP761: Broad Potential Targeting Auto-Reactive Memory T Cells Deficiency in LAG3 Pathways Linked to IMP761 Immutep’s proprietary humanized IgG4 Development of Autoimmune Diseases LAG-3–specific antibody A LAG-3–Specific Agonist Antibody for the Treatment of T Cell–Induced Autoimmune Diseases Mathie
Slide 26: Summary
Summary 2022 Milestones Corporate Snapshot • Clinical data from TACTI-002 • Pioneering LAG-3 portfolio in oncology and ✓ 1L NSCLC Oral Presentation at ASCO autoimmune diseases with four product candidates in multiple clinical trials ✓ 2L NSCLC PD-X refractory data presented at European Lung Cancer C
Slide 27: Thank You
: =) immutep Thank You